Notice of ARCALIS’ Head Office Relocation
ARCALIS Inc. (headquartered in Kashiwa City, Chiba Prefecture) is pleased to announce that its head office was relocated to Minamisoma City, Fukushima Prefecture, where the construction of our new mRNA Drug Substance Plant was completed on August 4th, 2023.
| New Head Office | 320-20 Kawauchisako, Shimoota aza, haramachi, Minamisoma, Fukushima, 975-0041 |
|---|
[About ARCALIS] https://corp.arcalis.co.jp/en
ARCALIS is an mRNA vaccines and therapeutics contract development and manufacturing organization (“CDMO”), jointly established by Axcelead, Inc. (President & CEO, Yoshinori Ikeura, hereafter, Axcelead) and Arcturus Therapeutics, Inc. (NASDAQ: ARCT/hereafter, Arcturus). ARCALIS aims to develop the world’s first mRNA vaccines and therapeutics CDMO business that promises a stable supply of high-quality mRNA medicines to all customers, including pharmaceutical companies, biotech companies, and academic institutes worldwide. The new facility in the city of Minamisoma (Fukushima prefecture) is equipped with state-of-the-art manufacturing and quality control systems that meet the cGMP standards for pharmaceuticals.